FDA approval of CBD triggers shift in seizure disorder diagnosis

In June 2018, the FDA approved Epidiolex, a pharmaceutical-grade CBD medication, specifically for treating seizures associated with Lennox-Gastaut syndrome (LGS)—a severe form of childhood epilepsy. This landmark approval represented the first cannabis-derived drug approved by the FDA and generated significant attention in both medical and cannabis communities. The researchers investigated whether this approval had an impact on how LGS cases were diagnosed and reported in the United States, examining trends in diagnostic practices around the time of the FDA decision.

The study examined whether increased awareness and legitimacy of CBD treatment influenced medical professionals' diagnostic patterns for LGS. By analyzing LGS incidence data before and after FDA approval, the researchers could identify whether there was a meaningful change in how frequently physicians diagnosed the condition. This type of analysis is important because increased diagnosis rates following a major FDA approval could indicate either genuine improvements in diagnostic practices or simply increased awareness and detection of an underdiagnosed condition.

The findings have significant implications for understanding how FDA approval of cannabis-based medicines affects clinical practice and public health. The research highlights the complex relationship between regulatory approval, medical awareness, and patient diagnosis—suggesting that major policy decisions don't just change treatment options, but can also influence how conditions are identified and managed in clinical settings.